Trial Profile

A Phase 1 Dose-escalation Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult Participants

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 15 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PGT 121 (Primary) ; PGT 121 (Primary) ; TMB-380 (Primary) ; TMB-380 (Primary)
Indications HIV infections; HIV-1 infections
Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics

31 Jan 2023 Status changed from active, no longer recruiting to completed.
23 Aug 2022 Planned End Date changed from 5 Aug 2022 to 17 Jan 2023.
23 Aug 2022 Planned primary completion date changed from 5 Aug 2022 to 17 Jan 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com